Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Yi-Jen Fang 1 Article
Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
Chen-Wang Chang, Shu-Chen Wei, Jen-Wei Chou, Tzu-Chi Hsu, Chiao-Hsiung Chuang, Ching-Pin Lin, Wen-Hung Hsu, Hsu-Heng Yen, Jen-Kou Lin, Yi-Jen Fang, Horng-Yuan Wang, Hung-Hsin Lin, Deng Cheng Wu, Yen Hsuan Ni, Cheng-Yi Wang, Jau-Min Wong
Intest Res 2014;12(4):287-292.   Published online October 27, 2014
DOI: https://doi.org/10.5217/ir.2014.12.4.287
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan and Korea. We aim to explore the efficacy of using adalimumab in CD patients under such stringent criteria.

Methods

A retrospective analysis was conducted in nine medical centers in Taiwan and we collected the results of CD patients receiving adalimumab from Sep 2009 to Mar 2014. The clinical characteristics, response measured by CDAI (Crohn's Disease Activity Index), adverse events and survival status were recorded and analyzed. CR-70, CR-100, and CR-150 were defined as attaining a CDAI decrease of 70, 100 or 150 points compared with baseline.

Results

A total of 103 CD patient records were used in this study. Sixty percent of these patients received combination therapy of adalimumab together with immunomodulators. CR-70 was 68.7%, 74.5% and 88.4% after week 4, 8 and 12 of treatment, respectively. The steroid-free rate, complications and survival were 47.6%, 9.7% and 99% of patients, respectively. In considering the mucosal healing, only 25% patients achieve mucosal healing after treatment for 6 to 12 months. Surgery was still needed in 16.5% of patients. Combination treatment of adalimumab with immunomodulators further decreased the level of CDAI at week 8 when compared with the monotherapy.

Conclusions

Even under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria.

Citations

Citations to this article as recorded by  
  • Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents
    Omar I. Saadah, Turki AlAmeel, Ahmed Al Sarkhy, Mohammed Hasosah, Abdulrahman Al-Hussaini, Majid A. Almadi, Badr Al-Bawardy, Talal A. Altuwaijri, Mohammed AlEdreesi, Shakir A. Bakkari, Othman R. Alharbi, Nahla A. Azzam, Abdulelah Almutairdi, Khalidah A. A
    Saudi Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
    Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
    Advances in Digestive Medicine.2023; 10(1): 28.     CrossRef
  • Seronegative spondyloarthropathy-associated inflammatory bowel disease
    Chrong-Reen Wang, Hung-Wen Tsai
    World Journal of Gastroenterology.2023; 29(3): 450.     CrossRef
  • Is the frequency of dietitian support associated with greater clinical improvements in adults with Crohn's disease undertaking exclusive enteral nutrition?
    Liz Purcell, Rumbidzai Mutsekwa, Rebecca Angus, Dheeraj Shukla, Michelle Palmer
    Journal of Human Nutrition and Dietetics.2022; 35(3): 435.     CrossRef
  • The Antinociceptive Effect of Adalimumab, a TNF-Alpha Inhibitor, in a Mice Model of Inflammatory Pain
    Mehmet ÖZ, Hasan ŞİMŞEK
    Türk Doğa ve Fen Dergisi.2022; 11(3): 89.     CrossRef
  • Clinical features and treatment of inflammatory bowel disease in a low-incidence area
    Hsu-Heng Yen, Tsui-Chun Hsu, Mei-Wen Chen, Pei-Yuan Su, Yang-Yuan Chen
    Medicine.2021; 100(10): e25090.     CrossRef
  • Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
    Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
    Intestinal Research.2019; 17(1): 54.     CrossRef
  • Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
    Mauro Mastronardi, Margherita Curlo, Elisabetta Cavalcanti, Osvaldo Burattini, Renato Cuppone, Romina Tauro, Stefania De Santis, Grazia Serino, Pasqua Letizia Pesole, Elisa Stasi, Maria Lucia Caruso, Rossella Donghia, Vito Guerra, Pietro Giorgio, Marcello
    Frontiers in Medicine.2019;[Epub]     CrossRef
  • Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
    Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
    Intestinal Research.2018; 16(1): 4.     CrossRef
  • Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
    Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
    Journal of Gastroenterology and Hepatology.2018; 33(1): 20.     CrossRef
  • High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
    Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
    Intestinal Research.2018; 16(4): 588.     CrossRef
  • Balloon-Assisted Enteroscopy and Capsule Endoscopy in Suspected Small Bowel Crohn’s Disease
    Hsu-Heng Yen, Chen-Wang Chang, Jen-Wei Chou, Shu-Chen Wei
    Clinical Endoscopy.2017; 50(5): 417.     CrossRef
  • Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea
    Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun-Ho Lee, Kiju Chang, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Digestive Diseases and Sciences.2017; 62(10): 2882.     CrossRef
  • Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study
    Chrong-Reen Wang, Chia-Tse Weng, Chung-Ta Lee, Kuo-Yuan Huang, Sheng-Min Hsu, Ming-Fei Liu
    Scientific Reports.2017;[Epub]     CrossRef
  • Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease
    Jae Hee Cheon
    Journal of Gastroenterology and Hepatology.2017; 32(4): 769.     CrossRef
  • Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
    Zong Mei Zhang, Wei Li, Xue Liang Jiang
    Gut and Liver.2016; 10(2): 262.     CrossRef
  • Crohn's Disease: Specific Concerns in the Elderly
    Wei-Chen Lin, Ming-Jen Chen, Cheng-Hsin Chu, Tsang-En Wang, Horng-Yuan Wang, Shou-Chuan Shih, Chen-Wang Chang
    International Journal of Gerontology.2016; 10(3): 126.     CrossRef
  • Efficacy of Adalimumab in Korean Patients with Crohn's Disease
    Il Woong Sohn, Sung Tae Kim, Bun Kim, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Gut and Liver.2016; 10(2): 255.     CrossRef
  • Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Chang Kyun Lee, Hyo Jong Kim, Kang-Moon Lee, You Sun Kim, Chang Soo Eun, Sung-Ae Jung, Suk-Kyun Yang, Jun Lee, Tae-Oh Kim, Yunho Jung, Geom Seog Seo, Soon Man Yoon
    Gut and Liver.2016;[Epub]     CrossRef
  • Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes
    Vyvyca J. Walker, Alisha P. Griffin, Dagan K. Hammar, Paul F. Hollenberg
    The Journal of Pharmacology and Experimental Therapeutics.2016; 357(3): 537.     CrossRef
  • Laparoscopic bowel resection for pediatric inflammatory bowel disease
    Justin B. Mahida, Lindsey Asti, Katherine J. Deans, Peter C. Minneci, Benedict C. Nwomeh
    Journal of Surgical Research.2015; 199(1): 130.     CrossRef
  • 5,689 View
  • 59 Download
  • 20 Web of Science
  • 21 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP